(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Hundreds of Intact Dinosaur Eggs Emerge From 72-Million-Year Time Capsule - 2The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- 3Vote In favor of Your Favored Shimmering Water
- 4German finance minister sees advantages of smartphones in schools
- 5More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Vote In favor of Your Favored Web-based Venture Stage
- Figure out how to Amplify Your Open Record Reward
- Senegal president signs tough new anti-LGBT law doubling jail terms
- Photos: Presidential turkey pardons — a look back
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- New law puts familiar drinks, creams and gummies in legal limbo
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Does physics say that free will doesn't exist?
- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
